Cervical cancer is almost ubiquitously caused by persistent human papillomavirus (HPV) infection. The advent of vaccines and vaccination programs against HPV hold promise for dramatic reductions and elimination of cervical dysplasia and cancer. Currently, screening consists of cytology and/or HPV-based testing. Guidelines for timing of screening and subsequent management of abnormalities are critical for the delivery of effective care and to work toward the eradication of this highly preventable disease. In this chapter, we will review the natural history and epidemiology of HPV, the role of vaccination, the development and continued progress in screening for cervical dysplasia, and appropriate management, focusing on the adoption of risk-based management.
|Title of host publication||DiSaia and Creasman Clinical Gynecologic Oncology|
|Number of pages||19|
|State||Published - Jan 1 2023|
- cervical cancer
- Cervical dysplasia